Simplify Logo

Full-Time

Senior Director

Assay Development

Posted on 7/15/2024

Karius

Karius

51-200 employees

Non-invasive diagnostic tests for infections

Data & Analytics
Consulting
Hardware
AI & Machine Learning
Financial Services
Biotechnology
Healthcare

Compensation Overview

$206.5k - $309.7kAnnually

Expert

San Carlos, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Ph.D. in molecular biology or related field
  • 10+ years of post Ph.D. biotech industry experience
  • Prior experience in NGS-based IVD product development required
  • Prior experience developing sample preparation instruments required
  • 4+ years of experience managing a research or development team
Responsibilities
  • Leading diagnostic test maturation through the development stages
  • Manage the execution of large-scale biotechnology and diagnostic product development initiatives
  • Serve as the technical lead on product development activities
  • Provide technical expertise and leadership in product development planning
  • Ensure product performance by employing proven product development practices
  • Oversee the design, development, optimization, and validation of diagnostic assays
  • Develop and implement protocols for assay development
  • Develop and execute a strategic plan for assay development
  • Identify and prioritize key projects
  • Stay current with industry trends and emerging technologies
  • Perform data analysis with advanced analytical and statistical tools
  • Set clear goals, provide regular feedback and support professional development
  • Work closely with cross-functional teams
  • Communicate project status, results, and challenges to senior management
  • Represent the assay development team in internal and external meetings

Karius focuses on medical diagnostics for infectious diseases, offering the Karius Test, a liquid biopsy that detects over 1,000 pathogens from a single blood sample. This non-invasive test is quick and helps clinicians treat hospitalized patients by reducing the need for multiple invasive tests that can delay treatment. The Karius Test utilizes advanced genomics and artificial intelligence to identify microbial cell-free DNA (mcfDNA) in the bloodstream, providing insights into the pathogens responsible for infections. Karius differentiates itself from competitors by offering a faster, non-invasive alternative to traditional diagnostic methods, which can save lives and lower healthcare costs. The company's goal is to enhance infectious disease diagnostics through continuous learning and improvement of their machine learning algorithms and genomic databases.

Company Stage

Series C

Total Funding

$345M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

16%

1 year growth

13%

2 year growth

11%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $100M in Series C funding from prominent investors like Khosla Ventures and 5AM Ventures positions Karius for significant expansion and technological advancement.
  • The Karius Test's ability to detect a wide range of pathogens quickly can lead to faster treatment decisions, potentially saving lives and reducing healthcare costs.
  • The addition of experienced board members, including those from Khosla Ventures and Gilde Healthcare, brings valuable expertise and strategic guidance to the company.

What critics are saying

  • The high cost of advanced genomic diagnostics may limit widespread adoption, particularly in resource-constrained healthcare settings.
  • The competitive landscape in medical diagnostics is intense, with numerous companies vying for market share, which could impact Karius's growth.

What makes Karius unique

  • Karius leverages advanced genomics and AI to detect over 1,000 pathogens from a single blood sample, offering a non-invasive and rapid diagnostic alternative unlike traditional methods.
  • The continuous updating of their reference genome databases ensures that Karius stays at the forefront of infectious disease diagnostics, providing real-time insights.
  • The FDA Breakthrough Device designation for the Karius Test underscores its innovative approach and potential impact on the diagnosis and management of infectious diseases in immunocompromised patients.
INACTIVE